Abstract
Purpose
Despite treatment advances in hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) metastatic breast cancer (mBC), patients still experience reduced health-related quality of life (HRQoL). This study investigated concordance between patient-physician reported symptoms and side effects, and the impact of reporting on HRQoL among patients with HR+/HER2- mBC.
Methods
Data were derived from the Adelphi Real World Advanced Breast Cancer Disease Specific Programme (DSP)™, a cross-sectional survey of physicians and their patients with HR+/HER2- mBC receiving treatment, conducted in Europe and the United States between August 2022 and February 2023. Physicians reported patient characteristics, symptoms and side effects. Patients reported symptoms, side-effects and HRQoL using validated instruments. Descriptive, linear regression, and patient-physician concordance analyses were performed.
Results
Overall, 298 physicians provided data on 1,642 patients, of which 321 patients self-reported data. Tiredness (85.6%), general worry (75.9%), and worry about future health (75.9%) were the most common patient-reported symptoms and side effects overall. Physicians reported bone pain (30.3%) and appetite changes (13.2%) as the most frequent patient symptoms, while estimating that most patients experienced no side effects (55.1%). Concordance between patient-physician symptom reporting was generally low (kappa ≤ 0.20), with higher concordance associated with better HRQoL across multiple measures (p < 0.001).
Conclusion
Patients with HR+/HER2- mBC experience substantial disease and treatment-mediated side effects, with low patient-physician concordance associated with worse HRQoL. These results underscore the value of capturing patient-reported experiences to better characterize symptom burden and quality of life.
Clinical trial number
Not applicable.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s10549-026-08129-7.
Keywords: Advanced breast cancer, HRQoL, Alignment, HR+/HER2-
Introduction
Breast cancer remains the most frequently diagnosed cancer among women, accounting for an estimated 2.3 million new cases and one in six cancer-related deaths in women worldwide in 2022 [1]. Incidence has been rising, driven by a range of country-specific factors including population aging, shifts in reproductive and lifestyle-related risk factors, and disparities in access to essential health services [1]. Metastatic breast cancer (mBC) is the most advanced stage of breast cancer [2, 3]. mBC can be classified as recurrent or de novo metastatic (stage IV) disease [4], with over 60% of patients progressing to mBC after being originally diagnosed with early stage breast cancer [5–7]. Breast cancer prognosis and characteristics vary according to biomarker status [8], with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) mBC the most common subtype, accounting for approximately 70% of cases in the United States (US) [9]. Compared to other subtypes, HR+/HER2- mBC is associated with a more favorable prognosis [7, 9, 10]. However, the 5-year survival rate remains relatively low at 37% [9].
Despite recent advances in the treatment of HR+/HER2- mBC [11], many patients still struggle with symptoms, side effects, poor treatment adherence, and diminished health-related quality of life (HRQoL) [12–14]. These issues can negatively affect both the patient experience and clinical outcomes such as survival. Perception and reporting of these issues can also vary between patients and physicians. While several studies have highlighted the limited concordance between physician and patient reporting of symptoms and side effects [15–20], few have examined how these discrepancies relate to patients’ HRQoL [15, 16], and none focused specifically on the HR+/HER2- mBC population. A comprehensive understanding of the real-world symptom and side effect burden experienced by HR+/HER2- mBC patients, including how these are perceived by both patients and physicians, is an essential step towards improving patient-centered care and optimizing clinical outcomes.
This study aimed to characterize both physician-reported and patient-reported symptoms and side effects among patients receiving treatment for HR+/HER2- mBC in Europe and the US. We also analyzed the concordance between patient- and physician-reported symptoms and side effects, to understand the extent to which alignment on symptom reporting was associated with patients’ HRQoL.
Methods
Study design
Secondary data were taken from the Adelphi Real World Advanced Breast Cancer Disease-Specific Programme (DSP)™, a multifaceted cross-sectional survey, with elements of retrospective data collection via patient chart review, of treating physicians and patients with advanced breast cancer in a real-world clinical setting. Data collection was conducted in France, Germany, Italy, Spain, United Kingdom (UK), and the US from August 2022 to February 2023. The methodology has been previously described [21, 22], validated [23], and demonstrated to be consistent over time [24].
A geographically representative sample of physicians was recruited to participate in the survey, following completion of a short screening questionnaire. Physicians were eligible if they specialized as oncologists, were involved in the management of patients with mBC (stage IV), and saw at least five patients with mBC per month at the time of data collection. Patients were eligible for inclusion if they were ≥ 18 years old, were managed by physicians for mBC (stage IV), were identified by physicians as having HR+/HER2- mBC biomarker subtype, were receiving any line of treatment for mBC, and were not enrolled in a clinical trial at the time of data collection.
Physicians completed an attitudinal survey that focused on their perceptions of the disease, treatment, and mBC patients. Physicians then completed structured patient record forms for their next seven consecutively consulting patients with mBC (four of which were receiving first line [1L] treatment and three receiving second line or later [2L+]), though the number of completed forms varied across physicians. This provided representative cross-sectional real-world data on patients, utilizing both their clinical expertise and existing patient records. Physicians completed these forms at the time of patient’s clinical visit, and in consultation with evidence available in medical records, to mitigate against recall bias. This was reflective of real-world patient management. Physician participation was financially incentivized, with reimbursement upon survey completion according to fair market research rates.
Patients then provided informed consent and were invited to voluntarily complete a confidential questionnaire. These questionnaires were completed independently from their physician at the point of consultation and were returned in a sealed envelope, ensuring the patient’s responses were kept confidential from their physician. Patients provided perspectives about their own experiences, enabling analyses of corresponding patient-physician information on a subset of patients. Patients were not compensated for participation.
Physician-reported data
Physicians reported data on patient demographics, clinical and treatment characteristics, via patient chart review. Physicians provided data on the presence or absence of patient symptoms and side effects (either yes or no) in separate structured pre-defined lists, recorded both at diagnosis of mBC (where data were available in patients’ medical records) and at the time of the patient’s clinical visit (at point of data collection). Additionally, physicians subjectively assessed whether these symptoms had developed or worsened following the initiation of treatment, based on their knowledge of the patients’ history and in reference to medical records.
Patient-reported assessment
Patient-reported questionnaires were completed at the point of consultation, including questions on the experience and impact of mBC on their lives. Patients provided information on symptoms and side effects present at the time of survey, collected using validated HRQoL instruments, including the European Organization for Research and Treatment of Cancer Quality of Life questionnaire with a breast cancer-specific module (EORTC QLQ-C30/BR23) [25, 26], the EQ-5D-5L [27–29], and the Work Productivity and Activity Impairment (WPAI) questionnaire [30].
The 23-item EORTC QLQ-BR23 is an integrated system for assessing HRQoL by evaluating disease symptoms and treatment side effects. It consists of four functional scales and four symptom scales, rating problems from 1 to 4 (no problem at all to very much a problem) [25, 26]. Linear transformations were used to standardize the raw score, with reference values provided as benchmarks for results [25, 31].
EQ-5D-5L is a validated measure capturing health and HRQoL at the time of data collection across five dimensions, scored on a scale of 1 to 5 (no problems to extreme problems) [29]. The EQ-5D Visual Analogue Scale (EQ-5D VAS) assessed the individual’s subjective perception of their health on the day of evaluation, using a vertical analogue scale from 0 to 100 (worst health imaginable to best health imaginable) [27].
The WPAI questionnaire measures the impact of health problems on work productivity and daily activities across four domains: (a) absenteeism, (b) presenteeism, (c) overall work impairment score, and (d) non-work activities. Higher percentages indicate higher impairment for WPAI measures [30].
Ethical considerations
Patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval [32]. The survey materials were submitted to the Pearl Independent Institutional Review Board (IRB; #22-ADRW-150) and were deemed to be exempt.
In addition, the survey were performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996 [33], and Health Information Technology for Economic and Clinical Health Act legislation [34].
Data analysis
Patients were analyzed descriptively by treatment class. Treatment class groups at any line were: chemotherapy monotherapy, endocrine therapy (ET) and cyclin-dependent kinase 4 and 6 inhibitors (ET+CDK4/6i), ET and chemotherapy (ET+chemotherapy), ET monotherapy, other targeted therapy, and other.
Other targeted therapy includes any targeted drug therapy received in combination (including alpelisib, bevacizumab, everolimus), or another therapy not listed by physicians but indicated to be a targeted therapy. Other includes any other treatment, used either in combination or as a monotherapy, not listed above. Data on antibody-drug conjugates were not collected, due to these being unavailable in Europe at the time the survey was conducted.
The level of agreement between physician- and patient-reported symptom data was analyzed, where corresponding symptom and side effect data as reported by both the physician and their patient were available. Cohen’s kappa coefficient (k) was used to quantify agreement on reported symptoms and side effects [35]. The kappa statistic measures inter-rater reliability while accounting for agreement occurring by chance. A k value of 1 indicates perfect agreement, whereas a value of 0 suggests agreement no better than chance. Interpretation of k values followed established guidelines: <0 = poor agreement, 0.01–0.20 = slight agreement, 0.21–0.40 = fair agreement, 0.41–0.60 = moderate agreement, 0.61–0.80 = substantial agreement, and 0.81-1.00 = almost perfect agreement.
To enable the assessment of association of patient-physician discordance on HRQoL outcomes, linear regression analyses were performed using individual disagreements as predictors [36]. Separate regressions were performed for HRQoL summary scores. The effect estimates reflect the amount of increase or decrease in the outcome (certain HRQoL score) that would be associated with a 1 unit increase in the covariate (e.g., patient age).
Elastic net regression assessed which symptoms or side effects alignment were important predictors of each HRQoL outcome [37], as determined by the alignment’s effects on the following patient-reported outcome measures: EQ-5D-5 L, EQ-5D VAS score, EORTC global health status, and WPAI activity impairment. All variables of interest were inputted, and the model selected associated variables and determined the coefficients. Multicollinearity was accounted for, and no p-values were generated. The following covariates were adjusted for all regression analyses: patient age, disease stage (recurrent or de novo mBC), and treatment received at data collection.
Means (standard deviations [SD]), or medians and interquartile ranges (IQR) were calculated for continuous variables as appropriate, and frequency counts and percentages for categorical variables. Patient characteristics between patients who completed self-reported forms and those who did not were compared using bivariate analyses. Statistical significance was defined as p < 0.05.
All analyses were conducted in Stata v18 [38]. Missing data were not imputed; therefore, the base of patients for analysis could vary from variable to variable and was reported separately for each analysis.
Results
Overall, 298 physicians provided data on 1642 patients in their care diagnosed with HR+/HER2- mBC. Of these, 321 patients self-reported data via voluntary questionnaire completion (Supplementary Figure 1).
Most patients were over the age of 65 years old at data collection (56.5%, n = 928), were White (90.9%, n = 1493) and had de novo mBC at the time of mBC diagnosis (68.4%, n = 1123; Table 1). At data collection, 60.5% (n = 994) had received one line of therapy in the mBC setting. ECOG performance status score at the start of current treatment was 0 or 1 in 82.5% of patients (n = 1354). The most common treatment regimen across lines was ET+CDK4/6i (55.5%, n = 911). Median follow-up since mBC diagnosis was 11.5 (4.8–24.8) months.
Table 1.
Patient characteristics
| All patients n = 1642 |
|
|---|---|
| Age at data collection, years Median (IQR) <45 years, n (%) 45 to < 65 years, n (%) 65 + years, n (%) |
66 (58.0–72.0) 55 (3.3) 659 (40.1) 928 (56.5) |
|
Race1, n (%) White African American Hispanic/LatinX Afro-Caribbean Middle Eastern Asian (other) Asian (Indian subcontinent) South-East Asian Native American Other |
1493 (90.9) 35 (2.1) 43 (2.6) 29 (1.8) 13 (0.8) 12 (0.7) 11 (0.7) 6 (0.4) 2 (0.1) 3 (0.2) |
|
ECOG score at start of current treatment, n (%) 0 1 2+ |
380 (23.1) 974 (59.3) 287 (17.5) |
|
Disease State at mBC diagnosis2, n (%) Recurrent De Novo |
510 (31.1) 1123 (68.4) |
|
Treatment Regimen (across all lines)3, n (%) ET monotherapy ET+CDK4/6i ET+chemotherapy Chemotherapy monotherapy Other targeted therapy4 Other |
217 (13.2) 911 (55.5) 30 (1.8) 258 (15.7) 207 (12.6) 19 (1.2) |
|
Number of treatment lines received, n (%) 1 L 2 L 3 L 4 L+ |
994 (60.5) 619 (37.4) 17 (1.0) 12 (0.7) |
|
Time since mBC diagnosis, months Median (IQR) |
n = 1544 11.5 (4.8–24.8) |
|
Sites of metastases at data collection*, n (%) Bone Lungs Lymph nodes Liver Skin Malignant effusion Peritoneum Brain/CNS Adrenal glands Stomach Other |
n = 1640 1150 (70.1) 633 (38.6) 624 (38.0) 435 (26.5) 102 (6.2) 83 (5.1) 53 (3.2) 50 (3.0) 25 (1.5) 4 (0.2) 33 (2.0) |
1L, first-line; 2L+, second-line or later; ADC, antibody drug conjugate; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; CNS, central nervous system; ECOG, Eastern Cooperative Oncology Group performance status; ET, endocrine therapy; IQR, interquartile range, mBC, metastatic breast cancer
Missing data denotes unknown responses as reported by physicians. Unknown responses were excluded from analysis for some variables; in these instances, the sample size (n) is specified in the variable description to indicate the denominator
1 Physicians were permitted to select multiple response options for this variable when reporting on their patients. As such, the sum of percentages exceeds 100%, with each percentage representing the proportion of patients for whom physicians selected that particular option
2 De novo mBC disease was defined as patients first presentation of breast cancer being metastatic (stage IV). Recurrent disease was defined as patients having progressed to mBC from an earlier stage (0-IIIc) of breast cancer
3 ET monotherapy was defined as the use of a single hormone therapy including fulvestrant, anastrozole, letrozole, exemestane, tamoxifen, raloxifene, and toremifene, medroxyprogesterone acetate, megestrol acetate, and other hormone therapy (specific drug not listed by physicians but indicated to be hormone therapies)
ET+CDK4/6i was defined as the combined use of any ET listed above with a CDK4/6i (ribociclib, palbociclib, or abemaciclib)
ET+chemotherapy was defined as the combined use of any ET listed above in combination with a chemotherapy treatment including capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, liposomal doxorubicin, epirubicin, eribulin, etoposide, gemcitabine, ixabepilone, methotrexate, mitomycin, mitoxantrone, nab paclitaxel, paclitaxel, vinorelbine, 5-fluorouracil + other chemotherapy (specific drug not listed by physicians but indicated to be chemotherapy)
Chemotherapy monotherapy was defined as the use of any chemotherapy listed above, with no other treatment
Other targeted therapy includes any targeted drug therapy received in combination (including alpelisib, bevacizumab, everolimus), or another therapy not listed by physicians but indicated to be a targeted therapy
Other includes any other treatment, used either in combination or as a monotherapy, not listed above
4 Zero patients received ADC therapy
No differences were found between characteristics of patients who did or did not provide self-reported data (Supplementary Table 1).
Patient-reported symptoms and side effects
Of the 319 patients who completed the EORTC-QLQ-C30/BR23, the most frequently-reported issues were tiredness (85.6%, n = 273), worrying about future health (75.9%, n = 242), and general worry (75.9%, n = 242; Table 2). These were commonly-reported regardless of current treatment regimen or line of therapy (Supplementary Tables 2 and 3).
Table 2.
Patient-reported symptoms and side effects presence – overall
| Symptoms and side effects, n (%) | All Patients n = 319 |
|---|---|
| Tired | 273 (85.6) |
| Worry | 242 (75.9) |
| Worried about future health | 242 (75.9) |
| Needing to rest | 232 (72.7) |
| Felt weak | 222 (69.6) |
| Felt tense | 213 (66.8) |
| Difficulty sleeping | 211 (66.1) |
| Pain | 208 (65.2) |
| Depression | 193 (60.5) |
| Hot flushes | 180 (56.4) |
Top 10 most commonly reported symptoms and side effects are shown in order of prevalence in the overall cohort
Data presented were collected via voluntary pen-and-paper patient self-completion questionnaires. Sample sizes reflect the number of patient responses available for each question. Missing data indicates questions where patients did not provide a response
By treatment class, pain was reported by 80.8% of those who received chemotherapy monotherapy (n = 42), compared with 51.1% of those who received other targeted therapies (n = 24) and 63.6% who received ET+CDK4/6i (n = 110). Shortness of breath was reported by 63.2% of those who received ET monotherapy (n = 24) and 43.4% who received ET+CDK4/6i (Supplementary Table 2). By line of treatment, the most reported symptoms and side effects were the same across treatment groups (Supplementary Table 3).
The mean (SD) standardized patient-reported emotional, cognitive and social functioning domain scores were 69.0 (23.2), 76.0 (22.5) and 70.5 (25.1), compared to EORTC reference values of 72.0 (22.3), 81.7 (21.7) and 74.9 (30.4) for patients in EORTC trials, respectively [31]. The range in mean EORTC scores observed was no larger than 13.1 points (emotional functioning: ET monotherapy, 66.9 [26.5]; other treatment, 80.0 [7.5]) at diagnosis across current treatment class or current line number groups (Fig. 1).
Fig. 1.

Patient-reported EORTC scores across: (a) Emotional functioning domain; (b) Cognitive functioning domain; (c) Social functioning domain. 1L, first-line; 2L+, second-line plus; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; chemo, chemotherapy; EORTC, European Organization for Research and Treatment of Cancer; ET, endocrine therapy; RV, reference value; SD, standard deviation. EORTC QLQ-C30 scoring ranges 0-100, a high score indicates high capability and good quality of life, a low score indicates low capability. Data presented were collected via voluntary pen-and-paper patient self-completion questionnaires. Sample sizes reflect the number of patient responses available for each question. Missing data indicates questions where patients did not provide a response.
Physician-reported symptoms and side effects
Bone pain was the most common physician-reported symptom, affecting 30.3% (n = 496) of patients, followed by change in appetite (13.2%, n = 216) and weight loss (11.6%, n = 190). Overall, physicians reported that 30.9% (n = 506) of patients were asymptomatic (Table 3), ranging from 17.8% (chemotherapy monotherapy, n = 46) to 36.4% (ET+CDK4/6i, n = 63) and 36.8% (other treatment, n = 7) across treatment class groups (Table 4).
Table 3.
Physician-reported patient symptoms/side effects at the time of data collection – overall
| Symptom, n (%) | All Patients n = 1637 |
|---|---|
| Bone pain | 496 (30.3) |
| Change in appetite | 216 (13.2) |
| Weight loss | 190 (11.6) |
| Anxiety | 133 (8.1) |
| Difficulty sleeping | 116 (7.1) |
| Cough | 115 (7.0) |
| Dyspnea on exertion | 101 (6.2) |
| Shortness of breath | 97 (5.9) |
| Depression | 88 (5.4) |
| Breast pain | 70 (4.3) |
| Asymptomatic | 506 (30.9) |
| Side effects, n(%) |
All Patients n = 1642 |
| Neutropenia | 183 (11.1) |
| Joint/Muscle Pain | 176 (10.7) |
| Diarrhea | 145 (8.8) |
| Fatigue/Asthenia | 116 (7.1) |
| Nausea | 98 (6.0) |
| Anemia | 88 (5.4) |
| Loss of appetite | 69 (4.2) |
| Back pain | 65 (4.0) |
| Mood changes | 47 (2.9) |
| Hair loss/thinning/alopecia | 42 (2.6) |
| Experienced no side effects | 905 (55.1) |
Top 10 most commonly reported symptoms and side effects are shown in order of prevalence in the overall cohort.Missing data denotes unknown responses as reported by physicians. Unknown responses were excluded from analysis for some variables; in these instances, the sample size (n) is specified in the variable description to indicate the denominator
Table 4.
Physician-reported symptoms/side effects at the time of data collection – by treatment class
| Symptom, n (%) | ET monotherapy n = 216 |
ET+CDK4/6i n = 909 |
ET+ chemotherapy n = 30 |
Chemotherapy monotherapy n = 258 |
Other targeted therapy1 n = 205 |
Other n = 19 |
|---|---|---|---|---|---|---|
| Bone pain | 79 (36.6) | 253 (27.8) | 14 (46.7) | 82 (31.8) | 62 (30.2) | 6 (31.6) |
| Change in appetite | 30 (13.9) | 93 (10.2) | 2 (6.7) | 58 (22.5) | 32 (15.6) | 1 (5.3) |
| Weight loss | 26 (12.0) | 70 (7.7) | 3 (10.0) | 55 (21.3) | 34 (16.6) | 2 (10.5) |
| Anxiety | 11 (5.1) | 75 (8.3) | 4 (13.3) | 20 (7.8) | 23 (11.2) | 0 (0.0) |
| Difficulty sleeping | 13 (6.0) | 47 (5.2) | 3 (10.0) | 33 (12.8) | 20 (9.8) | 0 (0.0) |
| Cough | 10 (4.6) | 60 (6.6) | 1 (3.3) | 23 (8.9) | 19 (9.3) | 2 (10.5) |
| Dyspnea on exertion | 10 (4.6) | 44 (4.8) | 0 (0.0) | 32 (12.4) | 14 (6.8) | 1 (5.3) |
| Shortness of breath | 11 (5.1) | 31 (3.4) | 2 (6.7) | 30 (11.6) | 22 (10.7) | 1 (5.3) |
| Depression | 11 (5.1) | 48 (5.3) | 1 (3.3) | 16 (6.2) | 11 (5.4) | 1 (5.3) |
| Breast pain | 7 (3.2) | 31 (3.4) | 3 (10.0) | 20 (7.8) | 9 (4.4) | 0 (0.0) |
| Asymptomatic | 63 (29.2) | 331 (36.4) | 6 (20.0) | 46 (17.8) | 53 (25.9) | 7 (36.8) |
| Side effect, n(%) |
ET monotherapy n = 217 |
ET+CDK4/6i n = 911 |
ET+ chemotherapy n = 30 |
Chemotherapy monotherapy n = 258 |
Other targeted therapy 1 n = 207 |
Other n = 19 |
| Neutropenia | 1 (0.5) | 142 (15.6) | 3 (10.0) | 17 (6.6) | 19 (9.2) | 1 (5.3) |
| Joint/Muscle Pain | 35 (16.1) | 85 (9.3) | 6 (20.0) | 23 (8.9) | 23 (11.1) | 4 (21.1) |
| Diarrhea | 6 (2.8) | 84 (9.2) | 2 (6.7) | 33 (12.8) | 20 (9.7) | 0 (0.0) |
| Fatigue/Asthenia | 6 (2.8) | 60 (6.6) | 3 (10.0) | 26 (10.1) | 19 (9.2) | 2 (10.5) |
| Nausea | 7 (3.2) | 40 (4.4) | 3 (10.0) | 26 (10.1) | 21 (10.1) | 1 (5.3) |
| Anemia | 1 (0.5) | 49 (5.4) | 1 (3.3) | 21 (8.1) | 14 (6.8) | 2 (10.5) |
| Loss of appetite | 3 (1.4) | 29 (3.2) | 3 (10.0) | 14 (5.4) | 20 (9.7) | 0 (0.0) |
| Back pain | 11 (5.1) | 34 (3.7) | 3 (10.0) | 6 (2.3) | 10 (4.8) | 1 (5.3) |
| Mood changes | 11 (5.1) | 27 (3.0) | 0 (0.0) | 4 (1.6) | 3 (1.4) | 2 (10.5) |
|
Hair loss/thinning/ alopecia |
1 (0.5) | 23 (2.5) | 1 (3.3) | 12 (4.7) | 4 (1.9) | 1 (5.3) |
| Experienced no side effects | 151 (69.6) | 507 (55.7) | 14 (46.7) | 119 (46.1) | 104 (50.2) | 10 (52.6) |
ADC, antibody drug conjugate; CDK4/6i, cyclin-dependent kinase 4/6 inhibitor; ET, endocrine therapy. Top 10 most commonly reported symptoms and side effects are shown in order of prevalence in the overall cohort
1 Zero patients received ADC therapy
Missing data denotes unknown responses as reported by physicians. Unknown responses were excluded from analysis for some variables; in these instances, the sample size (n) is specified in the variable description to indicate the denominator
ET monotherapy was defined as the use of a single hormone therapy including fulvestrant, anastrozole, letrozole, exemestane, tamoxifen, raloxifene, and toremifene, medroxyprogesterone acetate, megestrol acetate, and other hormone therapy (specific drug not listed by physicians but indicated to be hormone therapies)
ET+CDK4/6i was defined as the combined use of any ET listed above with a CDK4/6i (ribociclib, palbociclib, or abemaciclib)
ET+chemotherapy was defined as the combined use of any ET listed above in combination with a chemotherapy treatment including capecitabine, carboplatin, cisplatin, cyclophosphamide, docetaxel, doxorubicin, liposomal doxorubicin, epirubicin, eribulin, etoposide, gemcitabine, ixabepilone, methotrexate, mitomycin, mitoxantrone, nab paclitaxel, paclitaxel, vinorelbine, 5-fluorouracil + other chemotherapy (specific drug not listed by physicians but indicated to be chemotherapy)
Chemotherapy monotherapy was defined as the use of any chemotherapy listed above, with no other treatment
Other targeted therapy includes any targeted drug therapy received in combination (including alpelisib, bevacizumab, everolimus), or another therapy not listed by physicians but indicated to be a targeted therapy
Other includes any other treatment, used either in combination or as a monotherapy, not listed above
Physicians reported that 55.1% (n = 905) of patients experienced no side effects, while the most common side effect was neutropenia (11.1%, n = 183; Table 3). By treatment class, the proportion of patients reported to be experiencing no side effects ranged from 69.6% (n = 151) in patients receiving ET monotherapy, to 46.1% (n = 119) of patients receiving chemotherapy monotherapy. In the ET+CDK4/6i group, neutropenia was reported for 15.6% (n = 142) of patients, while in the ET monotherapy group this was 0.5% (n = 1). In both chemotherapy-based groups (ET + chemotherapy and chemotherapy monotherapy), most patients experienced side effects (Table 4). By line of therapy, most of those on 1L therapy and 2L+ experienced no side effects (57.1% and 52.0%, respectively; Supplementary Table 4).
Using a combination of retrospective data from patient clinical records and data gathered at the point of consultation, physicians indicated whether symptoms or side effects had emerged or worsened since treatment initiation. The only symptom that worsened in over 10% of the overall cohort was bone pain severity (11.5%, n = 120; Supplementary Table 5).
By treatment, 10.3% of the chemotherapy monotherapy group (n = 20) and 10.3% those receiving other targeted treatments (n = 15) were reported to have a worsened change in appetite, while no other treatment group experienced this for more than 5.5% of patients (ET+CDK4/6i). Neutropenia worsened for 3.8% (n = 20) of the ET+CDK4/6i group and 4.1% (n = 6) of those receiving other targeted therapies, while no other treatment group experienced worsening neutropenia in over 0.7% of patients (ET monotherapy; Supplementary Table 6). Symptom worsening data is shown by treatment line in Supplementary Table 7.
Concordance of patient- and physician-reported symptoms and side effects
A comparison of symptom and side effects as reported by both physicians and patients was undertaken, in cases where corresponding data from both the physician and their patient were available. As quantified by Cohen’s kappa, agreement on the reporting of symptom and side effect presence ranged from poor to fair across all items. The lowest levels of agreement were observed for visual changes (k= -0.01) and constipation (k = 0.00) symptoms, with data indicating poor agreement between patients and physicians. Across all symptoms and side effects, only diarrhea and bone pain showed fair concordance (k = 0.25 and 0.22, respectively; Fig. 2). Physician-reported symptoms and side effects mapped to patient-reported EORTC QLQ-C30 and BR23 items can be found in Supplementary Table 8.
Fig. 2.

Concordance between physician- and patient-reported: (a) Symptoms; (b) Side effects. Kappa analyses were run to investigate concordance between patients and physicians in the reporting of symptom or side effect presence. When patients and their physicians both reported that a symptom or side effect was present, kappa scores were higher, indicating higher concordance. The sample size for each symptom and side effect varies because only patients with corresponding responses from both the physician and patient on that specific item were included in the concordance analysis. Corresponding pairs were unavailable when patients did not respond to a question or when physicians reported symptoms or side effects for their patient as unknown
Higher overall concordance on symptoms and side effects was significantly associated with better HRQoL, as measured by the EQ-5D-5 L, EQ-5D-VAS, and EORTC QLQ-C30 global health status scores, and with lower percent activity impairment as measured by the WPAI (Supplementary Table 9). When looking at specific symptoms or side effects, patient-physician alignment on shortness of breath, abdominal pain, and depression presence/absence showed strong associations with improved HRQoL outcomes, per EORTC scores (Fig. 3).
Fig. 3.

Patient-physician symptom alignment as predictors of patient HRQoL. Elastic net regression analyses were performed to assess the association between patient-physician alignment in each symptom and side effect’s reporting, and the patient’s HRQoL, as determined by the patient-reported outcome measure scores. Higher coefficient scores indicate stronger associations between increase in patient-physician concordance and increase in the patient-reported outcome measure score, while lower coefficient scores indicate increased patient-physician concordance reduced the patient-reported outcome measure score. For EQ-5D-5 L score, EQ-5D VAS Score and EORTC QLQ-C30 global health status, higher scores are indicative of better HRQoL. For WPAI non-work activity impairment, lower scores indicate lower impairment and thus better HRQoL, Grey boxes indicate no association was found between patient-physician alignment and patient’s HRQoL. EQ-5D-VAS, EQ-5D-visual analogue score; EORTC, European Organisation for Research and Treatment of Cancer Quality of Life questionnaire with a breast cancer-specific module; HRQoL, health-related quality of life; WPAI, work productivity and activity impairment questionnaire; -ve, negative; +ve, positive
Discussion
In this study, patients with HR+/HER2- mBC self-reported a high prevalence of fatigue, physical weakness, and emotional distress. Conversely, physicians most frequently reported bone pain, change in appetite, and weight loss, while estimating that nearly a third of patients experienced no symptoms and over half experienced no side effects. Notably, concordance between patient- and physician-reported symptoms and side effects was generally low, with higher agreement associated with better HRQoL outcomes.
Although most patients in the study were in the early stages of HR+/HER2- mBC treatment, most patients experienced symptoms and side effects. These findings align with prior research on HR+/HER2- mBC, which identified fatigue, bone pain, and sleep disturbances as common patient-reported symptoms [39–43]. Less common symptoms such as dyspnea, appetite loss, gastrointestinal issues, and hair loss were also observed. Psychosocial impacts, including elevated worry and suboptimal emotional, cognitive, and social functioning (as measured by the EORTC), were found in our study, aligning with prior research [39, 42].
Despite some variation in the least commonly-reported symptoms, we found that the most frequently-reported symptoms and side effects, including psychosocial ones, were prevalent across treatment classes. While targeted therapies like CDK4/6i were linked to some symptom improvement compared to chemotherapy in prior studies, the overall burden remains high for patients with HR+/HER2- mBC [42–44]. One study reported that HRQoL among patients with advanced breast cancer declined between 2005 and 2015 [45], underscoring the persistent challenge of symptom and side effect management regardless of therapeutic advances.
Given this substantial symptom burden, it is essential to consider the broader treatment goals of HR+/HER2- mBC patients. Prior studies have shown that patients with advanced breast cancer often prioritize survival benefits over improved side effect profiles [46, 47]. This prior research is relevant to our study’s symptom burden findings, with our data indicating that greater patient-physician alignment on reporting of symptom and side effects was associated with greater patient HRQoL. As survival rates improve with the introduction of new biomarker-directed therapies, HRQoL is becoming a more important treatment consideration for patients. This highlights the importance of offering a range of treatment options, so that patients can select therapies that are individually tolerable and aligned with their treatment goals without compromising survival outcomes.
Our findings of low concordance between physician- and patient-reported symptoms align with previous research in both oncology and other populations [15–18, 20]. mBC symptoms have previously been shown to be underreported by physicians, aligning with the findings of our study [20]. While data specific to advanced breast cancer remain limited, our focus on HR+/HER2- mBC adds novel insight, particularly the potential association between symptom reporting discordance and patient HRQoL. Greater concordance may indicate more physician awareness of less-measurable clinical characteristics, and better communication between patients and physicians – vital components of an effective therapeutic relationship. Together with prior research linking depression and poor functional status to diminished HRQoL and treatment non-adherence in breast cancer patients [13, 48], our findings underscore the importance of effective patient–physician communication, which may improve treatment adherence and promote overall well-being. This is particularly relevant regarding recognition of symptoms relating to psychosocial health and overall HRQoL. These factors may not be of primary concern to oncologists who may focus more on survival outcomes, but could have been discussed separately by patients with their general practitioner. As new treatments improve survival rates in oncology, HRQoL becomes more important to patients, and thus our findings that there is a disconnect between patients and their physicians on the prevalence and impact of symptoms and side effects are highly relevant in this context. Taken together, this highlights the need for healthcare professionals to more holistically assess patient needs, symptoms and treatment expectations, as part of a broader multidisciplinary care plan.
Integrating real-time symptom reporting tools into clinical care has been proposed as a systemic improvement in healthcare delivery and has demonstrated survival benefits in patients with metastatic cancer [49]. While remote symptom monitoring represents a valuable long-term strategy, there remains an urgent need for improvements in patient–physician communication and shared decision-making to address current gaps in care.
Strengths and Limitations
Our study has strengths and limitations that should be acknowledged. The cross-sectional design restricts the ability to capture the temporal sequence between treatment administration and the onset of symptoms or side effects. Consequently, it was not possible to establish causal relationships between low concordance and HRQoL, or to clearly differentiate between symptoms attributable to mBC itself and side effects resulting from treatment; however, we were still able to identify significant associations.
While physicians were asked to provide data for a consecutive series of patients to avoid selection bias, this was a pragmatic, convenience sample recruitment approach. Patients who visited their physician more frequently, perhaps due to being more severely affected by their disease, had a higher likelihood of being included. Patients’ willingness to self-report data may have also been influenced by disease severity and various factors. Patients had to be fit and well enough to be seen by the physicians in person and able to complete the surveys, therefore, it is unlikely they were experiencing very severe symptoms or side effects at the time of consultation. In addition, as completion of the patient-reported questionnaire was voluntary and was not financially incentivized, this limited the availability of patient responses and may have introduced bias. Patients in this study were also receiving active oncology treatment for mBC, and the analysis excluded patients who died during treatment or discontinued active treatment. Therefore, the generalizability of our results to the broader experiences of patients with mBC is limited. Despite this, no significant differences were found between the characteristics of those who did or did not provide self-reported data in this study, suggesting that the sample of patients who self-reported data was representative of the overall patient sample.
The oncologists who participated in this study may not fully represent the broader population of oncologists in the studied region. To mitigate against this, a large sample of physicians was recruited from densely populated areas and screening criteria were applied to ensure that participating physicians had a relevant caseload.
While recall bias is a common limitation of surveys, the data for these analyses were collected at the time of each patient’s appointment to reduce this likelihood. In addition, physicians had access to patient medical records for data extraction.
In data analysis, patients provided symptom and side effect data via the EORTC tool, while physicians reported symptom and side effect data separately in their questionnaire. This meant that wording differences may have been present between patient and physician surveys. Therefore, assumptions were made to compare symptoms and side effects, e.g. comparing ‘feelings of worry’ (patient-reported) to ‘anxiety’ (physician-reported) when conducting concordance analysis.
In linear regression analyses, covariate selection was limited by sample size and multicollinearity concerns. The same covariate set was used across both linear regression and elastic net analyses to maintain consistency.
Despite these limitations, the study offers several notable strengths. This real-world study uniquely combines linked physician and patient perspectives to examine concordance on symptom and side effect reporting between physicians and their consulting patients with HR+/HER2- mBC, comprehensively describes the symptoms and side effects experienced, and explores the potential association between patient-physician alignment and patient HRQoL. Finally, the study employed a robust and validated methodology, which supports the reliability and credibility of the study results.
Conclusion
This study highlights the persistent symptom burden and HRQoL challenges faced by patients with HR+/HER2- mBC, even in early lines of treatment. We observed discordance between physician- and patient-reported symptoms, underscoring the need to better integrate patient perspectives into clinical discussions and treatment decisions. Improved communication between patients and physicians may help ensure that symptom burden and quality of life considerations are adequately recognized and addressed within disease management and supportive care planning.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
Editorial/medical writing support on behalf of Adelphi Real World (Bollington, United Kingdom) was provided by Maxwell Dobney, formerly of Adelphi Real World, Bollington, United Kingdom, and Gary Sidgwick, PhD CMPP, of Adelphi Real World, Bollington, United Kingdom under the guidance of the authors and in accordance with Good Publication Practice 2022 (GPP 2022) guidelines (https://www.ismpp.org/gpp-2022).
Author contributions
All authors were involved in (1) conception or design, or analysis and interpretation of data; (2) drafting and revising the article; (3) providing intellectual content of critical importance to the work described; and (4) final approval of the version to be published, and therefore meet the criteria for authorship in accordance with the International Committee of Medical Journal Editors (ICMJE) guidelines. In addition, all named authors take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
Funding
Data collection was undertaken by Adelphi Real World as part of an independent survey, entitled the Adelphi Real World aBC DSP. The analysis described here used data from the Adelphi Real World aBC DSP. The DSP is a wholly owned Adelphi Real World product. Gilead Sciences, Inc. was one of multiple subscribers to the DSP. Gilead Sciences, Inc. did not influence the original survey through either contribution to the design of questionnaires or data collection. Publication of survey results was not contingent on the subscriber’s approval or censorship of the manuscript. This study was supported by Gilead Sciences, Inc.
Data availability
All data, i.e. methodology, materials, data and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Annabel Lambert at annabel.lambert@omc.com.
Declarations
Ethical approval
Patients provided informed consent to take part in the survey. No identifiable protected health information was extracted during the survey. Data were collected in such a way that patients and physicians could not be identified directly, with data aggregated before being shared. Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines and as such did not require ethics committee approval. The survey materials were submitted to the Pearl Independent Institutional Review Board (IRB; #22-ADRW-150) and were deemed to be exempt. In addition, surveys were performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996, and Health Information Technology for Economic and Clinical Health Act legislation
Prior publication
Elements of the data presented in this manuscript were previously presented at the SABCS 2023 in San Antonio, Texas, USA, APOS 2024 in Albuquerque, New Mexico, USA, and ESMO BC 2025 conference in Munich, Germany.
Competing interests
Annabel Lambert and Chloe Hammond are employees of Adelphi Real World, Bollington, UK, and have no conflicts of interest to declare.MK Rehnquist, Nikoleta Sjekloca, and Anandaroop Dasgupta are employees and stockholders of Gilead Sciences, Inc.Cosmina Hogea is an employee and stockholder of Gilead Sciences, Inc. and holds stock or stock options in GSK and Pfizer.Gregory A. Vidal is a paid consultant (paid to self) for Roche/Genentech, Novartis, Eli Lilly, Gilead, Puma, Pfizer, AstraZeneca, Hologic, Daiichi Sankyo, Concerto AI, Stemline, Merck, and Arvinas; and receives payment or honoraria (paid to self) for lectures, presentations, speakers bureaus, manuscript writing or educational events from Eli Lilly, AstraZeneca; and Gilead; and participates (paid to self) on a Data Safety Monitoring Board or Advisory Board for Roche/Genentech, Novartis, Eli Lilly, Gilead, Pfizer, AstraZeneca, Daiichi Sankyo, Stemline, Merck, and Arvinas.Allison W. Kurian participates in collaborative research with no funding with Ambry, Caris, Color, Foundation, GeneDx, Gilead, GRAIL, Komodo, Labcorp, Merck, Merit, Myriad, Optum, Previvor and Tempus. Stephanie L. Graff has received grants or contracts (paid to institution) in the past 36 months from AstraZeneca, Novartis, Daiichi Sankyo, Lilly, Hoffmann-La Roche /Genentech, Menarini (Stemline) Group; and was a paid consultant (paid to self, relationships now ended) for Pfizer, SeaGen, AstraZeneca, DaiichiSankyo, Gilead Sciences, Menarini Stemline, Genentech, Novartis, Lilly/Loxo@Lilly; and is an unpaid volunteer in a leadership or fiduciary role for Dempsey Center for Quality Care, on the Board of Directors; and holds stock or stock options in HCA Healthcare.Celeste K. Nsubayi and Andrea N. Curry have no conflicts of interest to declare.
Footnotes
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
- 1.Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229–263 [DOI] [PubMed] [Google Scholar]
- 2.Wang R, Zhu Y, Liu X et al (2019) The Clinicopathological features and survival outcomes of patients with different metastatic sites in stage IV breast cancer. BMC Cancer 19(1):1091 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Mariotto AB, Etzioni R, Hurlbert M et al (2017) Estimation of the Number of Women Living with Metastatic Breast Cancer in the United States. Cancer Epidemiol Biomarkers Prev 26(6):809–815 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Walter CB, Hartkopf AD, Hein A et al (2025) Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer. Breast 80:104412 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Müller V, Hein A, Hartkopf AD et al (2022) Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics – A retrospective analysis of a real world registry. Eur J Cancer 172:13–21 [DOI] [PubMed] [Google Scholar]
- 6.Gallicchio L, Devasia TP, Tonorezos E et al (2022) Estimation of the Number of Individuals Living With Metastatic Cancer in the United States. JNCI: J Natl Cancer Inst 114(11):1476–1483 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Lobbezoo DJ, van Kampen RJ, Voogd AC et al (2013) Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat 141(3):507–514 [DOI] [PubMed] [Google Scholar]
- 8.Gennari A, André F, Barrios CH et al (2021) ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer☆. Ann Oncol 32(12):1475–1495 [DOI] [PubMed] [Google Scholar]
- 9.SEER. Cancer Stat Facts: Female Breast Cancer Subtypes National Cancer Institute: NIH.gov (2021) [updated 30/09/2025. Available from: https://seer.cancer.gov/statfacts/html/breast-subtypes.html
- 10.Gong Y, Liu Y-R, Ji P et al (2017) Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study. Sci Rep 7(1):45411 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Gombos A, Goncalves A, Curigliano G et al (2023) How I treat endocrine-dependent metastatic breast cancer. ESMO Open 8(2):100882 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Williamson TJ, Love SM, Clague DeHart JN et al (2018) Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE). Breast Cancer Res Treat 171(1):75–84 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Kokkonen K, Saarto T, Mäkinen T et al (2017) The functional capacity and quality of life of women with advanced breast cancer. Breast Cancer 24(1):128–136 [DOI] [PubMed] [Google Scholar]
- 14.daCosta DiBonaventura M, Copher R, Basurto E et al (2014) Patient preferences and treatment adherence among women diagnosed with metastatic breast cancer. Am Health Drug Benefits 7(7):386–396 [PMC free article] [PubMed] [Google Scholar]
- 15.Ribbands A, Boytsov N, Bailey A et al (2023) Real-world patient-reported outcomes and concordance between patient and physician reporting of side effects across lines of therapy in multiple myeloma within the USA. Support Care Cancer 31(6):371 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Chandwani KD, Zhao F, Morrow GR et al (2017) Lack of Patient-Clinician Concordance in Cancer Patients: Its Relation With Patient Variables. J Pain Symptom Manage 53(6):988–998 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Nekolaichuk CL, Bruera E, Spachynski K et al (1999) A comparison of patient and proxy symptom assessments in advanced cancer patients. Palliat Med 13(4):311–323 [DOI] [PubMed] [Google Scholar]
- 18.Chidambaram S, DeShields T, Potter P et al (2014) Patient and provider concordance on symptoms during the oncology outpatient clinic visit. J Community Support Oncol 12(10):370–377 [DOI] [PubMed] [Google Scholar]
- 19.Di Maio M, Gallo C, Leighl NB et al (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33(8):910–915 [DOI] [PubMed] [Google Scholar]
- 20.Umashankar S, Basu A, Esserman L et al (2023) Concordance between patient-reported and physician-documented comorbidities and symptoms among Stage 4 breast cancer patients. Cancer Med 12(22):20906–20917 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Anderson P, Benford M, Harris N et al (2008) Real-world physician and patient behaviour across countries: Disease-Specific Programmes - a means to understand. Curr Med Res Opin 24(11):3063–3072 [DOI] [PubMed] [Google Scholar]
- 22.Anderson P, Higgins V, Courcy J et al (2023) Real-world evidence generation from patients, their caregivers and physicians supporting clinical, regulatory and guideline decisions: an update on Disease Specific Programmes. Curr Med Res Opin 39(12):1707–1715 [DOI] [PubMed] [Google Scholar]
- 23.Babineaux SM, Curtis B, Holbrook T et al (2016) Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open 6(8):e010352 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Higgins V, Piercy J, Roughley A et al (2016) Trends in medication use in patients with type 2 diabetes mellitus: a long-term view of real-world treatment between 2000 and 2015. Diabetes Metab Syndr Obes 9:371–380 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Fayers PAN, Bjordal K, Groenvold M, Curran D, Bottomley A, EORTC Quality of Life Group (2001) EORTC QLQ-C30 Scoring Manual, 3rd edn. European Organisation for Research and Treatment of Cancer, Brussels [Google Scholar]
- 26.Michels FA, Latorre Mdo R, Maciel Mdo S (2013) Validity, reliability and understanding of the EORTC-C30 and EORTC-BR23, quality of life questionnaires specific for breast cancer. Rev Bras Epidemiol 16(2):352–363 [DOI] [PubMed] [Google Scholar]
- 27.EuroQol Group (1990) EuroQol - a new facility for the measurement of health-related quality of life. Health Policy 16(3):199–208 [DOI] [PubMed] [Google Scholar]
- 28.Brooks R (1996) EuroQol: the current state of play. Health Policy 37(1):53–72 [DOI] [PubMed] [Google Scholar]
- 29.Devlin N, Roudijk B, Ludwig K (2022) Value Sets for EQ-5D-5L: A Compendium. Comparative Review & User Guide. Springer Copyright 2022, The Editor(s) (if applicable) and The Author(s), Cham (CH). This book is an open access publication [PubMed] [Google Scholar]
- 30.Reilly MC, Zbrozek AS, Dukes EM (1993) The validity and reproducibility of a work productivity and activity impairment instrument. PharmacoEconomics 4(5):353–365 [DOI] [PubMed] [Google Scholar]
- 31.Mierzynska J, Taye M, Pe M et al (2020) Reference values for the EORTC QLQ-C30 in early and metastatic breast cancer. Eur J Cancer 125:69–82 [DOI] [PubMed] [Google Scholar]
- 32.European Pharmaceutical Market Research Association (EphMRA) Code of Conduct 2024 [updated September 2024. Available from: https://www.ephmra.org/sites/default/files/2024-09/2024%20EPHMRA%20Code%20of%20Conduct%20Final.pdf
- 33.US Department of Health and Human Services. Summary of the HIPAA Privacy Rule 2003 Available from: http://www.hhs.gov/sites/default/files/privacysummary.pdf
- 34.Health Information Technology (HITECH) Health Information Technology Act (2009) [Available from: https://www.healthit.gov/sites/default/files/hitech_act_excerpt_from_arra_with_index.pdf
- 35.Landis JR, Koch GG (1977) The Measurement of Observer Agreement for Categorical Data. Biometrics 33(1):159–174 [PubMed] [Google Scholar]
- 36.Horvath Walsh LE, Rider A, Piercy J et al (2019) Real-World Impact of Physician and Patient Discordance on Health-Related Quality of Life in US Patients with Acute Myeloid Leukemia. Oncol Ther 7(1):67–81 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Zou H, Hastie T (2005) Regularization and Variable Selection Via the Elastic Net. J Royal Stat Soc Ser B: Stat Methodol 67(2):301–320 [Google Scholar]
- 38.StataCorp (2023) Stata Statistical Software: Release 18. College Station. StataCorp LLC, TX [Google Scholar]
- 39.Davie A, Carter GC, Rider A et al (2020) Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2- advanced breast cancer in five European countries. BMC Cancer 20(1):855 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Davie A, Cuyun Carter G, Rider A et al (2021) Real-world clinical profile, treatment patterns and patient-reported outcomes in a subset of HR+/HER2- advanced breast cancer patients with poor prognostic factors: data from an international study. ESMO Open 6(4):100226 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Galipeau N, Klooster B, Krohe M et al (2019) Understanding key symptoms, side effects, and impacts of HR+/HER2- advanced breast cancer: qualitative study findings. J Patient Rep Outcomes 3(1):10 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Mahtani R, Niyazov A, Arondekar B et al (2022) Real-world patient-reported outcomes and physician satisfaction with poly (ADP-ribose) polymerase inhibitors versus chemotherapy in patients with germline BRCA1/2-mutated human epidermal growth factor receptor 2-negative advanced breast cancer from the United States, Europe, and Israel. BMC Cancer 22(1):1343 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Rocque GB, Blum JL, Ji Y et al (2025) Real-world quality-of-life of patients with HR+/HER2- advanced breast cancer treated with palbociclib plus endocrine therapy: EORTC QLQ-C30 results from POLARIS. Breast Cancer Res Treat 209(3):613–627 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Husinka L, Koerner PH, Miller RT et al (2020) Review of cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer. J Drug Assess 10(1):27–34 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Cardoso F, Spence D, Mertz S et al (2018) Global analysis of advanced/metastatic breast cancer: Decade report (2005–2015). Breast 39:131–138 [DOI] [PubMed] [Google Scholar]
- 46.Bland KA, Mustafa R, McTaggart-Cowan H (2023) Patient Preferences in Metastatic Breast Cancer Care: A Scoping Review. Cancers (Basel).;15(17) [DOI] [PMC free article] [PubMed]
- 47.Bullen A, Ryan M, Ennis H et al (2024) Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment. BMJ Open 14(4):e076798 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Hershman DL, Shao T, Kushi LH et al (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529–537 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Basch E, Deal AM, Dueck AC et al (2017) Overall Survival Results of a Trial Assessing Patient-Reported Outcomes for Symptom Monitoring During Routine Cancer Treatment. JAMA 318(2):197–198 [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data, i.e. methodology, materials, data and data analysis, that support the findings of this survey are the intellectual property of Adelphi Real World. All requests for access should be addressed directly to Annabel Lambert at annabel.lambert@omc.com.
